Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT07291778
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury
  • VExUS

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fluid Management — OTHER
    For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score: VExUS = 0: Recommend a net positive fluid balance. VExUS = 1: Recommend a net neutral fluid balance. VExUS \>= 2: Recommend a net negative fluid balance. These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
  • No intervention — OTHER
    Primary team will not be informed about the patient's VExUS score and will not be given recommendations for fluid management

Study Details

This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.

Key Dates

Start date
Jul 1, 2026
Status verified
Apr 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Informed
    The treating team receives the patient's VExUS results and management recommendations.
  • Placebo Comparator: Non-informed
    The treating team remains blinded to all VExUS findings and receives no feedback or recommendations.

Primary Outcome Measure

In-hospital Mortality [ Time Frame: up to 30 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at Birmingham Medical CenterBirminghamAlabama35294
Timothy I Kennell, MD, PhD
[email protected]
2059965864
Steve Fox, MD (PRINCIPAL_INVESTIGATOR)
Timothy I Kennell, MD, PhD (SUB_INVESTIGATOR)

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham Medical Center· Birmingham, AL

Related Studies